Treatment effect evaluation of endolymphatic hydrops by inner ear contrast-enhanced MRI

Treatment effect evaluation of endolymphatic hydrops by inner ear contrast-enhanced MRI - Treatment effect evaluation of endolymphatic hydrops by inner ear contrast-enhanced MRI

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032430

Enrollment

100

Registered

2018-04-30

Start date

2018-04-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meniere&#39

Interventions

Inner ear contrast-enhanced MRI

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: # Definitive Meniere's disease or delayed endolymphatic hydrops # Intractable case with frequent vertigo attacks (atleast once a month, for 6 months or over) # No renal problem (less than 0.9mg/dl serum creatinine)

Exclusion criteria

Exclusion criteria: # Previous adverse experiences with (contrast-enhanced) MRI # Braoncheal asthma symptoms within recent 10 years # In pregnancy and preconception # Other conditions considered as undesirable for entry in this clinica trial

Design outcomes

Primary

Measure	Time frame
Endolymphatic hydrops on the MR image	—

Countries

Japan

Contacts

Public ContactTakao IMAI

Osaka University Hospital Otolaryngology, Head and Neck Surgery

timai@ent.med.osaka-u.ac.jp06-6879-5575

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026